Understanding how Ponatinib causes vascular damage
Mechanism of Ponatinib induced vascular toxicity
This study is looking into how the cancer drug Ponatinib, used for treating chronic myelogenous leukemia, might increase the risk of heart problems and strokes, so we can find safer treatment options for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10900243 on NIH RePORTER |
What this research studies
This research investigates the harmful effects of Ponatinib, a medication used to treat chronic myelogenous leukemia (CML), particularly its association with increased risks of serious cardiovascular events like heart attacks and strokes. The study aims to uncover the mechanisms behind this vascular toxicity by examining how Ponatinib may inflame existing atherosclerotic plaques in patients. By analyzing the behavior of endothelial cells and the role of inflammatory cytokines, the research seeks to provide insights that could lead to safer treatment options for CML patients. The findings could help improve patient outcomes by addressing the cardiovascular risks associated with this therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic myelogenous leukemia who are being treated with Ponatinib and have pre-existing cardiovascular risk factors.
Not a fit: Patients who do not have chronic myelogenous leukemia or those who are not receiving Ponatinib may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment strategies for CML patients, reducing the risk of life-threatening cardiovascular events.
How similar studies have performed: While there have been studies on the effects of other Abl-tyrosine kinase inhibitors, the specific mechanisms of Ponatinib-induced vascular toxicity are still being explored, making this research a novel investigation.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Stepanian, Alec — Tufts University Boston
- Study coordinator: Stepanian, Alec
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.